Semi-Annual Report — FY2026 H1
What Oncolys BioPharma Inc. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-07View the original on EDINET
How much it says
59Typical
What moved here
28named for the first time
Its own wording
48terms
Which filing this is
34/ 34newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim accounting period (1 January 2026 to 30 June 2026), OBP-301 obtained marketing authorization on 8 June 2026, and the filing disclosed a planned start of sales on 21 August 2026 following approval of the proposed NHI price. It also stated that clinical trials for OBP-601 are progressing with all costs borne by Transposon Therapeutics. Financially, revenue increased year on year, while both an operating loss and an interim net loss were recorded.
Komori's summary of this document, not the document's own words.59Typical
How much this filing saysA weighted roll-up of 10 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
54
Typical
49
Typical
75
Very detailed
50
Typical
68
Detailed
71
Detailed
7
Almost nothing
79
Very detailed
60
Detailed
R&D spend8億円Money spent making new things.
Cash left over-10億円Cash from the business, less what went into equipment.
Spent on equipment1百万円Plants, machines — things meant to last.
Employees45Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.